Good points, hope it's true in terms of $30 price target, personally expecting it to settle around $25 but need to get some resolution on the Generics court date in January to even reach that. A positive surprise would be an expanded label that is less restrictive than street is guessing. I think street believes approval is going to happen, but there are some small doubts.
It's a big overhang but one most expect will go away. So by itself the catalyst is not as great as most would think but it will open up for more institutional investors and others to jump in that are waiting for AMRN to fully de-risk.
It also brings in the speculation of BO again.
It'll be interesting to see what happens with price post approval but people should temper stock price expectations a bit, it should solidly get it above $20 (FINALLY!) and if the generic suits get resolved I see $25, to get past that it all becomes about revenue growth if GIA so we will see how fast Amarin can raise sales.
In terms of your hedging, the fact anyone gave you crap about it is just a testament to the following and respect you got on this board, they just got scared that if you are hedging maybe there is an issue type of thing. It's just common sense for you to do it.
There are several people on the Facebook group posting they are all in on this stock, I get it but you should not go all in unless you are going to be OK if things go to the toilet because nothing is 100% guaranteed. I plan on going part-time and semi retire at 53 in a couple years, if Amarin goes to $3 I probably can still do that though adds more risk, if it goes to $30 plus makes that more comfortable. I could go ALL In and if it doubles I won't even need to be part time, but if it goes back to $3 I'm not retiring in any fashion anytime soon. Risk/Reward, smart to hedge even if risk is low that you need it.
